SABCS 2020: Some postmenopausal women with common breast cancer may forgo chemotherapy
Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer…
Browsing: TAILORx
TAILORx dispels chemo-brain notion: Women on hormone therapy also report cognitive decline
The Journal of Clinical Oncology reports that a subgroup of women on chemotherapy in the landmark TAILORx…
ESMO 2019: New data from the TAILORx study on cohort with recurrence score 26-100 shows 93% cancer-free rate at 5 years
A new analysis from TAILORx, the largest ever breast cancer treatment trial, has been published…
ASCO 2019: New TAILORx data guides adjuvant therapy in younger breast cancer patients
New information about adjuvant therapy to prevent recurrence of breast cancer in women 50 years…
SABCS 2018: Black women have worse breast cancer outcomes despite receiving similar treatment as white women
Even with equivalent treatments in women with hormone receptor-positive, HER2-negative breast cancer, black women had…
My Top 3 ASCO Abstracts by Prunella Blinman
I love a good plenary session at ASCO, and this year’s plenary session was one…
Most Women With Early Stage Breast Cancer Can Forgo Chemotherapy When Guided by a Diagnostic Test
A federally funded phase III clinical trial shows that most women with hormone receptor-positive, HER2-negative,…
More patients with early-stage breast cancer may be able to avoid chemotherapy in the future
For women with intermediate risk recurrence score from 21-gene expression assay, less may be more…